Search research articles
Contact Us
Filters
Showing results (371-380 of 409) with videos related to
Page
of 41
Sort By:
Journal of the American Chemical Society
|
June 13, 2025
Isomerization of Poly(ethylene glycol): A Strategy for the Evasion of Anti-PEG Antibody Recognition
Philip Dreier, Rebecca Matthes, Fabian Fuß, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 20, 2007
Sequenced compared with simultaneous anthracycline and cyclophosphamide in high-risk stage I and II breast cancer: final analysis from INT-0137 (S9313)
Hannah M Linden, Charles M Haskell, Stephanie J Green, et al.
Research Square
|
February 5, 2024
Repeatability of 18F-FDG uptake in metastatic bone lesions of breast cancer patients and implications for accrual to clinical trials
Mark Muzi, Lanell M Peterson, Jennifer M Specht, et al.
EJNMMI Research
|
March 27, 2024
Repeatability of <sup>18</sup>F-FDG uptake in metastatic bone lesions of breast cancer patients and implications for accrual to clinical trials
Mark Muzi, Lanell M Peterson, Jennifer M Specht, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
October 27, 2018
Test-Retest Reproducibility of <sup>18</sup>F-FDG PET/CT Uptake in Cancer Patients Within a Qualified and Calibrated Local Network
Brenda F Kurland, Lanell M Peterson, Andrew T Shields, et al.
Molecular Imaging and Biology
|
October 17, 2018
Correction to: a Phase 2 Study of 16α-[18F]-Fluoro-17β-Estradiol Positron Emission Tomography (FES-PET) as a Marker of Hormone Sensitivity in Metastatic Breast Cancer (MBC)
Lanell M Peterson, Brenda F Kurland, Erin K Schubert, et al.
EJNMMI Research
|
June 27, 2012
Feasibility study of FDG PET as an indicator of early response to aromatase inhibitors and trastuzumab in a heterogeneous group of breast cancer patients
Brenda F Kurland, Vijayakrishna K Gadi, Jennifer M Specht, et al.
Molecular Imaging and Biology
|
October 31, 2013
A phase 2 study of 16α-[18F]-fluoro-17β-estradiol positron emission tomography (FES-PET) as a marker of hormone sensitivity in metastatic breast cancer (MBC)
Lanell M Peterson, Brenda F Kurland, Erin K Schubert, et al.
Breast Cancer Research : BCR
|
November 10, 2023
Multimodal prediction of neoadjuvant treatment outcome by serial FDG PET and MRI in women with locally advanced breast cancer
Anum S Kazerouni, Lanell M Peterson, Isaac Jenkins, et al.
The European Journal of Neuroscience
|
June 28, 2005
Loss of zolpidem efficacy in the hippocampus of mice with the GABAA receptor gamma2 F77I point mutation
D W Cope, C Halbsguth, T Karayannis, et al.
Page
of 41
Search research articles
Search
Showing results (371-380 of 409) with videos related to
Sort By:
Page
of 41
Journal of the American Chemical Society
|
June 13, 2025
Isomerization of Poly(ethylene glycol): A Strategy for the Evasion of Anti-PEG Antibody Recognition
Philip Dreier, Rebecca Matthes, Fabian Fuß, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 20, 2007
Sequenced compared with simultaneous anthracycline and cyclophosphamide in high-risk stage I and II breast cancer: final analysis from INT-0137 (S9313)
Hannah M Linden, Charles M Haskell, Stephanie J Green, et al.
Research Square
|
February 5, 2024
Repeatability of 18F-FDG uptake in metastatic bone lesions of breast cancer patients and implications for accrual to clinical trials
Mark Muzi, Lanell M Peterson, Jennifer M Specht, et al.
EJNMMI Research
|
March 27, 2024
Repeatability of <sup>18</sup>F-FDG uptake in metastatic bone lesions of breast cancer patients and implications for accrual to clinical trials
Mark Muzi, Lanell M Peterson, Jennifer M Specht, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
October 27, 2018
Test-Retest Reproducibility of <sup>18</sup>F-FDG PET/CT Uptake in Cancer Patients Within a Qualified and Calibrated Local Network
Brenda F Kurland, Lanell M Peterson, Andrew T Shields, et al.
Molecular Imaging and Biology
|
October 17, 2018
Correction to: a Phase 2 Study of 16α-[18F]-Fluoro-17β-Estradiol Positron Emission Tomography (FES-PET) as a Marker of Hormone Sensitivity in Metastatic Breast Cancer (MBC)
Lanell M Peterson, Brenda F Kurland, Erin K Schubert, et al.
EJNMMI Research
|
June 27, 2012
Feasibility study of FDG PET as an indicator of early response to aromatase inhibitors and trastuzumab in a heterogeneous group of breast cancer patients
Brenda F Kurland, Vijayakrishna K Gadi, Jennifer M Specht, et al.
Molecular Imaging and Biology
|
October 31, 2013
A phase 2 study of 16α-[18F]-fluoro-17β-estradiol positron emission tomography (FES-PET) as a marker of hormone sensitivity in metastatic breast cancer (MBC)
Lanell M Peterson, Brenda F Kurland, Erin K Schubert, et al.
Breast Cancer Research : BCR
|
November 10, 2023
Multimodal prediction of neoadjuvant treatment outcome by serial FDG PET and MRI in women with locally advanced breast cancer
Anum S Kazerouni, Lanell M Peterson, Isaac Jenkins, et al.
The European Journal of Neuroscience
|
June 28, 2005
Loss of zolpidem efficacy in the hippocampus of mice with the GABAA receptor gamma2 F77I point mutation
D W Cope, C Halbsguth, T Karayannis, et al.
Page
of 41